Avastin plus radiation and chemo extends PFS in patients with aggressive brain cancer
This article was originally published in Scrip
Executive Summary
Roche and its Genentech unit plan to discuss with global regulatory authorities (including the European Medicines Agency and US FDA), new Phase III results showing that Avastin (bevacizumab) used with radiation and chemotherapy significantly extended the time people with an aggressive form of primary brain cancer lived without their disease getting worse.